BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate,

- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel - NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will host a webinar on its recently announced alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET

Vivos management to present at 1:30 pm Eastern Time on March 23, 2021

Using Science 37’s decentralized clinical trial model, the partnership offers Xperiome’s research-ready, rare disease patients more study opportunities with less burden.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021.

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism – Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company’s expertise and experience

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered during the NASH-TAG Conference being held March 11 th – 13 th .

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.

Ampicillin is a penicillin antibiotic drug that is specially used to prevent or treat numerous infections such as intestines, stomach, meningitis, gonorrhea, pneumonia, bladder infections, etc.